Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
March 04, 2024 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a...
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
February 28, 2024 09:14 ET
|
Cassava Sciences, Inc.
$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our...
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
February 07, 2024 09:08 ET
|
Cassava Sciences, Inc.
ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam...
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
January 05, 2024 09:12 ET
|
Cassava Sciences, Inc.
Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW”Warrant Holders Who Choose to Exercise During an Early Period Will Receive...
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
December 12, 2023 09:13 ET
|
Cassava Sciences, Inc.
Shareholders of Record Will Receive Warrants to Purchase Shares of Common Stock All Warrants to Be Distributed to Shareholders Free of ChargeWarrants Are Expected to List and Trade on NasdaqWarrant...
Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023 16:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of...
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023 09:01 ET
|
Cassava Sciences, Inc.
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected...
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023 09:15 ET
|
Cassava Sciences, Inc.
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023 09:15 ET
|
Cassava Sciences, Inc.
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. ...
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023 23:43 ET
|
Cassava Sciences, Inc.
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping...